ASH Atlanta 2021
The UKMF were delighted to award 5 joint bursaries to cover the virtual registration for ASH 2021 to the value of £450 each. The abstracts were judged from a panel made up from the Executive. The successful applicants will present their abstract at the Spring Day in March 2021 and will review the meeting for the e-newsletter.
Congratulations to the successful applicants:
Celgene: Hannah Giles – University of Birmingham, Specialist Registrar in Haematology
Sanofi: Zoe Craig – University of Leeds, Senior Medical Statistician
GSK: Roisin McAvera – Queen’s University of Belfast, PhD Researcher
Janssen-Cilag: Faouzi Djebbari – Churchill Hospital, Oxford, Advanced Haematology Pharmacist
Amgen: Annabel McMillan – Whittington & UCLH, Haematology Consultant
Documents
- Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment
- Multistate models demonstrate that lenalidomide maintenance enhances survival by prolonging time in first remission for patients treated in the UK NCRI Myeloma XI randomised trial
- TRIM33 Loss in Multiple Myeloma Impairs the DNA Damage Response Resulting in Sensitivity to PARP and ATR Inhibitors
- Efficacy outcomes of isatuximab with pomalidomide and dexamethasone are comparable to (ICARIA-MM) trial data: Initial results of a UK-wide real-world study of relapsed myeloma patients
- Daratumumab, Bortezomib and dexamethasone (DVd) at first relapse for patients with Relapsed/ Refractory Multiple Myeloma (RRMM): a UK Myeloma Research Alliance (UK-MRA) real-world multicentre analysis